Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olverembatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 17/20 | 0.94 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | FLT3 | P36888 | 1/20 | 0.94 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.94 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.94 |
| ▸ | KIT | P10721 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olverembatinib SCHEMBL14953403 | 1.00 | ABL1 (0.94) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29652687 | 1.00 | ABL1 (0.94) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29514988 | 0.97 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL3424528 | 0.97 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29387193 | 0.97 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL14953130 | 0.96 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29515011 | 0.96 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL30456095 | 0.96 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL30456239 | 0.93 | ABL1 (0.92) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| SCHEMBL22699129 | 0.92 | ABL1 (0.90) | ABL1FGFR1CYP2C9PDGFRACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-20220168316-A1 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS | CAMP4 THERAPEUTICS CORPORATION | 2022-06-02 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-11266655-B2 | Methods and compositions for treating urea cycle disorders | CAMP4 THERAPEUTICS CORPORATION (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | ABL1 4195/4885FGFR1 2153/4885CYP2C9 2141/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ABL1 2396/4885FGFR1 3001/4885CYP2C9 4789/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | ABL1 2110/4885FGFR1 2775/4885CYP2C9 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.